Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

NIH Grants & Funding for T-Cell Large Granular Lymphocyte Leukemia | Kisho | Kisho

Back to T-Cell Large Granular Lymphocyte Leukemia

T-Cell Large Granular Lymphocyte Leukemia — NIH Grants & Funding

Active and recent NIH-funded research on T-Cell Large Granular Lymphocyte Leukemia. Data from NIH RePORTER, last 36 months.

MONDO:0019469

Looking for specific grants? The Recent Research tab lets you search and filter by topic.

Funding Landscape

T-Cell Large Granular Lymphocyte Leukemia has emerging NIH research funding with 2 grants totaling $760K.

2funded grants from NIH

Portfolio: $760KCumulative: $760K1 active1 completed3 PIs2 institutions

By Research Theme

Basic Science

Translational

By Funding Mechanism

R01

R03

Funding Gap Analysis

Cross-referencing NIH grants against published research and clinical trials to identify funding-evidence gaps for T-Cell Large Granular Lymphocyte Leukemia. Strongest funded area: Translational / Drug Development. Largest gap: Epidemiology / Natural History.

Epidemiology / Natural HistoryPublished, Not NIH-Funded

11 publications in Case Report / Case Series but no NIH-funded grants found in Epidemiology / Natural History for T-cell large granular lymphocyte leukemia. Existing research activity suggests this may be a viable area for grant applications.

Adjacent Research(1 grant)

These grants mention T-Cell Large Granular Lymphocyte Leukemia as part of broader research but are not primarily focused on this disease. They are not included in the funding totals above.

Other(1)

OtherZIACompleted

Improved Chimeric Antigen Receptor Therapies B-cell Malignancies

Kochenderfer, James·DIVISION OF BASIC SCIENCES - NCI

$647,651 (FY2024)

NIH RePORTER

Top Funded Institutions

UNIVERSITY OF VIRGINIA$681K

VA1 grantLoughran, Thomas, Ratan, Aakrosh

OHIO STATE UNIVERSITY$79K

OH1 grantBrammer, Jonathan

Top Principal Investigators

Loughran, Thomas$681K

UNIVERSITY OF VIRGINIA·1 grant

Basic Science

Ratan, Aakrosh$681K

UNIVERSITY OF VIRGINIA·1 grant

Basic Science

Brammer, Jonathan$79K

OHIO STATE UNIVERSITY·1 grant

Translational